Operating losses have widened to $34.9 million in 2026Q1 as R&D spending reached $28.0 million, reflecting the company's transition into late-stage clinical validation.
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 574K | 0 | 0 | 1.29M | 0 | 0 | 0 | 509K |
| COGS % of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | -574K | 0 | 0 | -1.29M | 0 | 0 | 0 | -509K |
| Gross Margin % | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | 100% | - | - | - | 100% | - |
| Operating Expenses | 118.05M | 112.79M | 96.12M | 83.7M | 60.3M | 35.25M | 22.21M | 23.63M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 23.7M | 22.49M | 22.81M | 19.76M | 18.06M | 10.09M | 4.16M | 4.52M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - |
| Research & Development | 94.92M | 90.3M | 73.3M | 63.94M | 42.24M | 25.16M | 18.04M | 19.11M |
| R&D % of Revenue | - | - | - | - | - | - | - | - |
| Other Operating Expenses | -574K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -118.62M | -112.79M | -96.12M | -84.99M | -60.3M | -35.25M | -22.21M | -24.14M |
| Operating Margin % | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -17.35% | -13.09% | -40.96% | -71.05% | -58.74% | 8.01% | - |
| EBITDA | -117.5M | -111.66M | -94.89M | -83.7M | -59.12M | -34.42M | -21.38M | -23.63M |
| EBITDA Margin % | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -15.61% | -17.67% | -13.38% | -41.57% | -71.76% | -61.02% | 9.55% | - |
| D&A (Non-Cash Add-back) | 1.13M | 1.13M | 1.22M | 1.29M | 1.18M | 831K | 831K | 509K |
| EBIT | -116.98M | -112.79M | -96.12M | -84.99M | -60.3M | -35.25M | -22.21M | -24.2M |
| Net Interest Income | 6.23M | 6.63M | 9.43M | 8.59M | 1.86M | 0 | -3K | -5K |
| Interest Income | 6.23M | 6.63M | 9.43M | 8.59M | 1.86M | 13K | 3 | 5 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 13K | 3K | 5K |
| Other Income/Expense | 6.33M | 6.71M | 9.31M | 8.72M | 1.53M | -1K | 0 | -60K |
| Pretax Income | -112.29M | -106.08M | -86.81M | -76.27M | -58.76M | -35.25M | -22.21M | -24.2M |
| Pretax Margin % | - | - | - | - | - | - | - | - |
| Income Tax | 100K | 108K | 112K | 137K | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | -0.09% | -0.1% | -0.13% | -0.18% | 0% | 0% | 0% | 0% |
| Net Income | -112.39M | -106.19M | -86.92M | -76.41M | -58.76M | -35.25M | -22.21M | -24.2M |
| Net Margin % | - | - | - | - | - | - | - | - |
| Net Income Growth % | -18.69% | -22.17% | -13.76% | -30.03% | -66.7% | -58.75% | 8.24% | - |
| Net Income (Continuing) | -112.39M | -106.19M | -86.92M | -76.41M | -58.76M | -35.25M | -22.21M | -24.2M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.67 | -1.76 | -1.75 | -1.93 | -1.96 | -1.58 | -1.03 | -0.01 |
| EPS Growth % | 6.84% | -0.57% | 9.33% | 1.53% | -24.05% | -53.4% | - | - |
| EPS (Basic) | - | -1.76 | -1.75 | -1.93 | -1.96 | -1.58 | -1.03 | -0.01 |
| Diluted Shares Outstanding | 67.45M | 60.34M | 49.65M | 39.62M | 29.94M | 29.21M | 29.22M | 2.92B |
| Basic Shares Outstanding | 67.45M | 60.34M | 49.65M | 39.62M | 29.94M | 29.21M | 29.22M | 2.92B |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
Clinical trial execution failure
As reported in recent financial statements, AURA's research and development expenses have climbed to $28.0 million in 2026Q1, reflecting the intensified capital requirements of the pivotal Phase 3 CoMpass trial as the company transitions from early-stage development to late-stage clinical validation of its VDC platform.
The steady rise in R&D spending indicates a pivot toward high-cost, large-scale clinical execution, which is the primary driver of the company's current cash burn. Investors should monitor whether these costs stabilize or continue to accelerate as the company manages the logistical complexities of multi-site trial operations.
Based on the company's reported figures, operating losses have widened to $34.9 million in 2026Q1, demonstrating that the firm remains in a pre-revenue phase where operating expenses scale directly with clinical trial intensity rather than any underlying revenue-generating activity or operational efficiency gains.
The lack of revenue means that operating leverage is currently non-existent, as every dollar of R&D and SG&A directly impacts the bottom line. This structure implies that the company's financial health is entirely dependent on external capital markets until the VDC platform reaches commercial viability.
According to historical income statement data, AURA consistently records stock-based compensation expenses, such as the $3.7 million reported in 2025Q3, which serves as a non-cash mechanism to retain scientific talent while simultaneously diluting existing shareholders during this critical pre-revenue clinical development phase.
While SBC is a standard tool for biotech firms to preserve cash, the consistent reliance on equity-based incentives warrants close scrutiny regarding the true economic cost of operations. Analysts should adjust net income figures to account for these non-cash charges to better understand the company's actual cash-based burn rate.
Financial filings indicate a cash position of approximately $59.5 million, which appears increasingly insufficient when measured against the quarterly operating loss of $34.9 million, suggesting that the company faces a high probability of near-term dilutive financing to sustain its ongoing clinical trial programs.
The current burn rate implies that the company may exhaust its liquidity within two quarters, creating a significant overhang for investors. This financial pressure may force management to seek strategic partnerships or equity raises under potentially unfavorable terms if clinical milestones are not met in a timely manner.
Quick answers to the most common questions about buying AURA stock.
For fiscal year 2025, Aura Biosciences, Inc. (AURA) reported total revenue of $0.0M.
Aura Biosciences, Inc. (AURA) reported a net loss of $106.2M for the fiscal year ending 2025.